An evaluation of the budget impact of a new 20% subcutaneous immunoglobulin (Ig20Gly) for the management of primary immunodeficiency diseases in Switzerland
Richard F Pollock,1 Lisa M Meckley2 1Ossian Health Economics and Communications GmbH, Health Economics and Outcomes Research, Basel, Switzerland; 2Shire Plc, Outcomes Research and Epidemiology, Cambridge, MA, USA Introduction: While most individual primary immunodeficiency diseases (PID) are rare, t...
Saved in:
| Main Authors: | , |
|---|---|
| Format: | Book |
| Published: |
Dove Medical Press,
2018-04-01T00:00:00Z.
|
| Subjects: | |
| Online Access: | Connect to this object online. |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|